This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
by Zacks Equity Research
Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.
TVRDNegative Net Change NVAXNegative Net Change AMRNNegative Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
by Zacks Equity Research
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
NTLANegative Net Change BEAMNegative Net Change CRSPNegative Net Change
biotechs
Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?
by Sundeep Ganoria
Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.
VKTXNegative Net Change NVOPositive Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study
by Zacks Equity Research
AZN shares tumble after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising questions about its expansion into a larger market.
AZNNegative Net Change ALNYNegative Net Change IONSNegative Net Change BBIONegative Net Change
biotechs medical pharmaceuticals
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
by Zacks Equity Research
Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.
DNLINegative Net Change SNYNegative Net Change BIIBPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?
by Ekta Bagri
ADMA shares rebound 13.5% in a month after a steep decline, even as lowered 2026 guidance and IG market competition continue to weigh on sentiment.
ADMANegative Net Change GRFSNegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth
by Sundeep Ganoria
BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential U.S. launches.
BBIONegative Net Change PFENegative Net Change BMRNNegative Net Change ASNDNegative Net Change
biotechs medical pharmaceuticals
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead
by Sundeep Ganoria
BridgeBio Pharma's Attruby sales are surging, but can growth keep justifying its premium valuation amid execution risks and rising costs?
BBIONegative Net Change PFENegative Net Change BMRNNegative Net Change ASNDNegative Net Change
biotechs medical pharmaceuticals
BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts
by Sundeep Ganoria
BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its lone marketed therapy.
BBIONegative Net Change PFENegative Net Change BMRNNegative Net Change
biotechs medical pharmaceuticals
Axsome Begins Phase III Study on Solriamfetol for ADHD in Children
by Zacks Equity Research
AXSM doses the first patient in the phase III FOCUS-2 study of solriamfetol for treating ADHD in children aged six to under 12 years.
AXSMNegative Net Change JAZZNegative Net Change LQDANegative Net Change KNSANegative Net Change
biotechs